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Abstract
Background:Gastro-oesophagealrefluxdisease (GERD)
is a common disorder with consequences for the pa-
tient’s health-related quality of life (HRQol). In Ger-
many, few data are available on the impact of GERD
on work-related productivity.
Aim: to study the impact of GERD on work produc-
tivity despite proton pump inhibitor (PPI) therapy and
the association between productivity and symptom du-
ration, severity, and HRQol.
Methods: Retrospective  data  from  randomly  selected
patients with chronic GERD symptoms, treated by of-
fice-based  general  practitioners  or  general  internists
with routine clinical care, were analyzed together with
information  from  self-administered  instruments  as-
sessing work productivity (WPaI–GERD), symptoms
(RDQ), and HRQol (QolRaD).
Results: Reduced productivity was reported by 152 of
249 patients (61.0%), although 89.5% of them were
treated with PPI. the reduction in work productivity
was 18.5% in all patients and 30.3% in those with re-
duced productivity. Patients with impaired productivity
showed a significantly lower HRQol and more-severe
symptoms of reflux disease. In all patients, the mean
sick  leave  attributable  to  reflux  symptoms  was  0.6
hours in the previous seven days and 1.4 work days in
the previous three months.
Conclusion: GERD has a substantial impact on work
productivity  in  Germany,  even  in  patients  receiving
routine clinical care and PPI therapy.
Key  words: Gastro-oesophageal  reflux;  sick  leave;
Medical economics; Proton Pump Inhibitors
IntRoDuctIon
Gastro-oesophageal reflux disease (GERD) is a com-
mon and costly chronic disorder, with consequences
for the patient’s health-related quality of life (HRQol)
[1-3]. the prevalence of GERD has been estimated to
be between 10% and 20% in the Western world [1]. In
Germany, 14% of the adult population report moder-
ate reflux symptoms and 4% report severe symptoms
[4].  besides  esophageal  symptoms,  patients  suffer
from  chest  pain  and  a  variety  of  extra-esophageal
symptoms,  including  asthma,  chronic  cough,  and
laryngitis [5]. Esophageal and extra-esophageal symp-
toms are regarded as the reasons for the experience of
pain, lack of vitality, and feelings of poor physical and
mental health [6]. GERD substantially impairs all as-
pects of HRQol [6, 7]. 
the wide-ranging effects of GERD on health and
well-being  can  have  consequences  for  the  perfor-
mance of the affected individuals, particularly at work
[8]. In several studies that have analyzed measures of
work  productivity,  the  loss  of  productivity  ranged
from 6% to 42% among individuals with GERD [8].
GERD causes significant indirect costs attributable to
reduced productivity and time off work [9]. a Ger-
man study showed that 10% of total disease-related
costs  were  indirect  costs  arising  from  working  days
lost  to  illness  [2].  one  analysis  estimated  a  loss  of
gross domestic product of ᾬ688 million/year due to
GERD-related inability to work in Germany [10]. 
In Germany, the impact of GERD not only on the
ability to work [10] but also on overall work-related
productivity has been studied only once within an in-
ternational context [11]. the overall loss in productivi-
ty was 3.5 hours/week [11].  However, the results were
difficult  to  compare  because  a  non-standardized  in-
strument was used.
the aim of this study was to explore the extent of
GERD-induced  loss  of  work  productivity  (working
days lost and reduced productivity while working) in a
German primary-care patient population with chronic
reflux symptoms. the association between productivi-
ty  loss  from  GERD  symptoms  and  health-related
quality of life (HRQol) was also analyzed.
MatERIals anD MEtHoDs
stuDy subJEcts
In Germany, the initial management of GERD occurs
in primary care, provided by office-based physicians.
this includes a clinical evaluation, further diagnostic
procedures, and medical treatment [12]. therefore, pa-
tients  with  chronic  reflux  symptoms  were  randomly
selected from a sample of primary-care patients of of-
fice-based physicians (general practitioners [GPs] and
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7. Gross_Umbruchvorlage  17.03.10  11:09  Seite 124general internists) in the Munich area (both rural and
urban districts) in southern Germany. all physicians
cooperated with the “Health Management online” or-
ganization  (H-M-o  aG)  in  oberhaching,  southern
Germany, which selected the participating physicians.
seventeen of the 78 physicians which were invited to
participate  took  part  in  the  study  including  13  GPs
and  4  general  internists.  Data  for  this  retrospective,
multicenter  observational  study  were  collected  be-
tween July and november, 2007.
the inclusion criteria were: (1) at least 18 years old;
(2) at least one visit because of reflux symptoms more
than six months before study entry and a follow-up
visit  for  reflux  symptoms  between  six  and  three
months before study entry. these criteria were chosen
to  include  only  patients  with  chronic  reflux  disease.
GERD was diagnosed by the physicians according to
the International classification of Diseases, tenth Re-
vision (IcD 10), German Modification 2007, accord-
ing to the codes given in table 1. an upper endoscopy
recently or a longer time ago was not mandatory. the
exclusion criteria included other significant upper gas-
trointestinal  disorders  (including  Zollinger–Ellison
syndrome, gastric or duodenal ulcer, esophageal stric-
ture, and a history of dysplasia in barrett’s esophagus).
the physicians identified all patients in their office
database  who  fulfilled  the  inclusion  criteria.  an
anonymized  list  of  patients  was  transferred  to  the
study  organization  which  randomly  selected  the  pa-
tients. the patients were invited in writing to partici-
pate in the study and to make an appointment with
their  physician.  Written  informed  consent  was  ob-
tained from all patients before study entry. the pa-
tients  completed  the  questionnaires  in  the  office  of
their physician.
InstRuMEnts
Data  concerning  resource  use  and  treatment  within
the observation period over the preceding six months
was gathered retrospectively from patient records. to
measure  the  treatment  outcomes  and  the  patients’
GERD-related distress, a questionnaire was completed
by the participants, which included standardized vali-
dated  self-administered  instruments  to  assess  work
productivity and evaluate both symptoms and HRQol
in assessing the response to treatment.
Quality of  Life with Reflux and Dyspepsia (QOLRAD)
the  QolRaD  was  developed  to  assess  HRQol  in
patients suffering from GERD symptoms or dyspep-
sia [13]. the questionnaire consists of 25 items, which
are  organized  into  five  domains  (3–6  items  each):
emotional distress, sleep disturbance, eating and drink-
ing problems, physical/social functioning, and vitality.
the degree and frequency of distress and the patients’
feelings during the preceding week are assessed on a
seven-point likert scale, with a higher score represent-
ing less frequency or distress. although there is no de-
tailed  evaluation  of  QolRaD,  a  difference  of  ap-
proximately one point is considered to be clinically rel-
evant [14]. a German translation of QolRaD has
shown good psychometric qualities [15]. 
Reflux Disease Questionnaire (RDQ)
the original RDQ is a diagnostic instrument with 12
questions that evaluate the frequency and severity of
burning behind the sternum, pain behind the sternun,
upper stomach burning, upper stomach pain, acid taste
in the mouth, and movement of material during the
preceding four weeks [16]. a German version was cre-
ated to assess the treatment response for a shorter pe-
riod of one week using six-point scales ranging from
no occurrence to daily/severe [17]. this version has
been carefully validated and adequate validity, reliabili-
ty, and sensitivity have been demonstrated. With prin-
ciple components analysis, three factors (regurgitation,
heartburn, and dyspepsia) were identified. a combined
score for the factors regarding GERD symptoms (re-
gurgitation + heartburn) could be calculated.
Work Productivity and Activity Impairment
Questionnaire (WPAI–GERD)
the  WPaI–GERD  is  the  GERD-specific  validated
version  of  a  general  health  measure  that  has  been
modified for several health conditions [18]. It was de-
veloped to estimate the impact of heartburn and acid
regurgitation on productivity and has become a stan-
dard tool for the evaluation of work productivity [8,
19].  the  questionnaire  contains  three  open-ended
questions  about  hours  absent  from  work  for  health
reasons,  hours  absent  from  work  for  other  reasons,
and the number of hours worked during the last seven
days. the patients were instructed not to include the
time  spent  participating  in  the  study  as  time  absent
from work. In two further questions, patients rated the
impact of reflux symptoms on their productivity (per-
centage reduction in productivity at work). based on
the WPaI–GERD results, a work productivity score
(WPs) was calculated, which expresses the lost pro-
ductivity because of GERD symptoms for each pa-
tient as a percentage of their total potential productiv-
ity. a WPs of zero means no reduced productivity, a
value above zero means reduced productivity.
WPs = [(hours absent from work + percentage reduced
productivity at work ﾥ hours actually worked) /(hours ab-
sent from work + hours lost for other reasons + hours ac-
tually worked)] ﾥ 100
Absenteeism from work in the preceding three months
the  patients  were  asked  about  their  absenteeism
from  work  (hours  or  days)  in  the  preceding  three
months resulting from reflux symptoms, with or with-
out a medical certificate. In Germany, most employees
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Table 1. IcD 10 GERD diagnostic codes identifying Patients
with reflux disease.
code Diagnosis
k21 Gastroesophageal reflux disease 
k21.0 Gastroesophageal reflux disease with esophagitis - 
Reflux esophagitis
k21.9 Gastroesophageal reflux disease without esophagitis
R12 Heartburn - Excludes dyspepsia
7. Gross_Umbruchvorlage  17.03.10  11:09  Seite 125must present a medical certificate when absent from
work, although sometimes only when absent for more
than two days.
statIstIcal analysIs
to compare differences in the characteristics of the
samples, t tests were used for continuous variables and
c2 tests for discrete variables. all analyses were per-
formed with sPss 15.0 (sPss Inc., chicago, Il, usa).
HuMan subJEct PRotEctIon
this study was conducted in accordance with the lat-
est revision of the Declaration of Helsinski. the study
protocol was reviewed by the ethics committee of the
bavarian state chamber of Physicians.
REsults
PatIEnt cHaRactERIstIcs
a total of 627 patients with chronic GERD symptoms
were randomly selected from all the patients fulfilling
the inclusion criteria according to primary-care office-
based  GPs  and  internists.  two  hundred  sixty-five
(42.2%) of them were gainfully employed at the time
of  the  study  (31.4%  full-time  employment,  10.9%
part-time employment), 45.0% were retired, and 7.2%
were  unemployed.  two  hundred  forty-nine  (39.7%)
were  gainfully  employed,  completed  the  WPaI–
GERD,  and  were  therefore  included  in  the  analysis.
the proportion of males to females was 109 to 140,
with a mean age of 48.9 years. of the respondents,
50%  had  had  symptoms  of  GERD  for  at  least  3.5
years. Reduced productivity (WPs > 0) was reported
by 152 patients (61.0%). Patients with reduced produc-
tivity had suffered GERD symptoms for a significant-
ly shorter period than had patients whose productivity
was not reduced (mean 6.1 vs 9.1 years, respectively).
the  sex  distribution,  full-time  employment,  and
GERD diagnosis (IcD 10 codes) were similar in the
two groups (table 2). there were no significant differ-
ences in the use of either proton pump inhibitor (PPI)
medication (89%) or histamine-2-receptor antagonists
(13%)  between  patients  with  and  those  without  re-
duced  productivity.  Most  patients  were  treated  with
omeprazole  (51%  of  the  patients),  followed  by  es-
omeprazole (16%), pantoprazole (14%), lansoprazole
(1%), and rabeprazole (1%).
WoRk PRoDuctIvIty
for 6% of the respondents, their GERD symptoms
had been a cause of absenteeism in the preceding sev-
en days. on average, these patients missed 10.4 work-
ing hours in that week. the average absence resulting
from GERD reported by all 249 patients was 0.63 h in
that week (2.4% of work time).
the WPs is composed of absenteeism and reduced
productivity  while  working  attributable  to  GERD
symptoms, and refers to the total working time. In all
patients, WPs was 18.5 which means an average pro-
ductivity loss because of GERD symptoms of 18.5%
(table 3). In patients with reduced productivity, WPs
was 30.3.
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Table 2. study group characteristics
characteristic Working  no reduced  Reduced P value
patients productivity  productivity
total (WPs) (WPs)
n = 249  n = 97 n=152
Mean age [years (ﾱ sD)] 48.9 (11.5) 49.9 (11.7) 48.2 (11.3) 0.75
sex  [n (%)]
Male 109 (43.8) 46 (47.4) 63 (41.4) 0.36
female 140 (56.2) 51 (52.6) 89 (58.6)
Employment [n (%)]
full time 166 (66,7) 54 (55.7) 112 (73.7) 0.29
symptom duration
Mean [years (sD)] 7.3 (8.8) 9.1 (9.7) 6.1 (7.9) 0.01
Median [years (inner quartile range(] 3.5 (7.9) 5.6 (10.1) 2.8 (6.2) n/a
Diagnosis (IcD 10) [n (%)]*
k21 58 (23.3) 20 (20.6) 38 (25.0) 0.45
k21.0 101 (40.6) 43 (44.3) 58 (38.2) 0.36
k21.9 66 (26.5) 24 (24.7) 42 (27.6) 0.66
R12 72 (28.9) 29 (29.9) 43 (28.3) 0.89
Proton pump inhibitor use [n (%)]
yes 222 (89.1) 86 (88.7) 136 (89.5) 0.83
Histamine-receptor-2 use use [n (%)]
yes 33 (13.3) 10 (10.3) 23 (15.1) 0.27
*Multiple diagnoses possible
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how many working days had been lost during the pre-
ceding  three  months.  In  Germany,  many  employees
only require a medical certificate from a physician con-
firming their illness for an absence of more than two
days. In total, 1.35 ﾱ 4.83 working days were lost in
the last three months (table 4). the mean number of
lost working days among the 12.1% of all 249 patients
with absence from work was 11.1 ﾱ 8.89 days. the
overall mean number of working days lost with a med-
ical certificate for GERD was 0.59 ﾱ 2.78 days. this
kind of lost working days was reported by 7.1% of pa-
tients (mean 8.4 ﾱ 6.59 days). Patients also reported an
average of 0.76 ﾱ 3.67 lost working days without a
medical certificate (7.5% of patients with a mean loss
of 9.63 ﾱ 9.36 days).
Patients with reduced productivity during the pre-
ceding seven days showed significantly more lost work
days in the preceding three months (table 4). only the
days off without a medical certificate (usually less than
three days absence) differed significantly between the
two groups, not the days lost during a longer period of
inability to work.
HRQol
Reduced HRQol correlated significantly with im-
paired  productivity  (table  5).  Patients  with  reduced
productivity  showed  a  significantly  lower  HRQol 
in  all  dimensions  of  QolRaD.  the  largest  mean 
differences  were  observed  in  the  dimensions  “emo-
tional  distress”  (0.84  points)  and  “vitality”  (0.83
points). the lowest total scores were reported by pa-
tients with reduced productivity in the dimensions “vi-
tality”,  “sleep  disturbance”,  and  “food/drink  prob-
lems”.
syMPtoM sEvERIty
symptom assessment revealed a higher frequency of
GERD  and  worse  symptoms  during  the  preceding
seven days in patients with reduced work productivity
(table  6).  significant  differences  were  observed  on
each RDQ symptom scale for these patients. Regurgi-
tation  was  the  most  relevant  sign,  with  the  highest
mean score (1.84) and the greatest difference between
employees  without  reduced  productivity  and  those
with reduced productivity (–0.44).
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Table 3. Work productivity score (WPaI-GERD) for the last seven days in all patients and in patients with normal or reduced
productivity [mean (sD)].
component Working no reduced  Reduced P value
(time frame: last seven days) patients productivity productivity
total (WPs) (WPs)
n = 249 n = 97 n = 152
Hours absent from work because of reflux symptoms 0.63 (3.75) 0.0 0.65 (3.29) n/a
Percentage reduced productivity at work 17.6 (21.3) 0.0 28.9 (20.4) n/a
Work productivity score (WPs) 18.5 (22.5) 0.0 30.3 (21.8) n/a
Table 4. Working days lost due to GERD during the preceding three months.
type of working days lost  Working no reduced  Reduced P value
(time frame: last three months) patients productivity productivity
total (WPs) (WPs)
n = 249 n = 97 n = 152
total working days lost 1.35 (4.83) 0.57 (2.99) 1.84 (5.64) 0.02
working days lost with medical certificate 0.59 (2.79) 0.47 (2.64) 0.66 (2.88) 0.62
working days lost without medical certificate 0.76 (3.67) 0.09 (0.57) 1.18 (4.61) <0.01
Table 5. Health-related Quality of life (QolRaD) in all patients and in patients with normal or reduced productivity.
QolRaD dimension Working  no reduced Reduced Difference P value
patients productivity productivity
total (WPs) (WPs)
n = 249 n = 97 n=152
Emotional distress 5.34 (1.47) 5.85 (1.39) 5.01 (1.44) 0.84 <0.001
food/drink problems 5.17 (1.32) 5.52 (1.37) 4.95 (1.24) 0.58 <0.01
Physical/social functioning 5.87 (106) 6.29 (0.99) 5.60 (1.01) 0.68 <0.001
sleep disturbance 525 (1.48) 5.72 (1.46) 4.95 (1.41) 0.77 <0.001
vitality 5.17 (1.47) 5.67 (1.45) 4.84 (1.38) 0.83 <0.001
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this study evaluated a group of employed patients vis-
iting  a  GP  or  primary-care  internist  for  chronic
GERD symptoms. the analysis was based on retro-
spective data and self-administered instruments were
used to determine the extent of GERD-caused loss of
work  productivity  and  its  association  with  GERD
symptoms  and  HRQol.  to  the  best  of  our  knowl-
edge, this is the first German study to use the stan-
dardized disease-specific WPaI–GERD questionnaire
to quantify productivity loss and compare the results
with international studies.
of the patients evaluated, 12.1% had reported ab-
sence from work attributable to GERD symptoms in
the  preceding  three  months.  this  corresponds  very
well to the 14% of employed patients reporting days
of  sick  leave  in  the  preceding  year  in  the  German
ProGERD study [10].  sixty-one percent of the em-
ployed patients reported reduced productivity attribut-
able to GERD while at work in the preceding seven
days, resulting in a mean absence from work of 0.63
hours and a reduction of 18.5% in overall work pro-
ductivity (WPs 0,185). this absence from work and
WPs are lower than those reported in other studies.
among the swedish working population consulting a
GP for current or recent symptoms of heartburn, a
mean absence from work of 2.5 h per week was re-
ported, with a WPs of 23% [20]. In a study in spain
among patients with nocturnal heartburn, a mean ab-
sence from work of 1.4 h and a WPs of 26% were re-
ported [21]. these differences in sick leave may indi-
cate that socioethical or socioeconomic factors influ-
ence patients’ willingness to be absent from work be-
cause of reflux symptoms.
When the lost working days are extrapolated to the
total  number  of  working  days  (1.35  of  65  working
days in three months), an average of 2.1% in three
months  was  calculated,  only  slightly  lower  than  the
2.4%  of  lost  work  time  measured  with  the
WPaI–GERD in the preceding seven days. only one
study in spain used a similar approach and reported
absenteeism of the same magnitude [22]. the German
ProGERD study reported that 2.5 working days had
been lost because of GERD in the year before the pa-
tients’ inclusion in the study [10]. this difference of
2.5 days/year versus 1.35 days/three months may be
the  result  of  recall  bias.  When  patients  report  their
days off work for the preceding year, the data proba-
bly  underestimate  the  disease-related  absences  from
work. It has been shown that there is a relevant recall
bias even when self-reported absences from work in a
four-week recall period are compared with those for a
two or one week period [23]. therefore, our finding of
1.35 lost working days in three months may be an ac-
curate estimate of the days lost to work in Germany.
Respondents with reduced productivity (WPs > 0)
had significantly more days off without a medical cer-
tificate (indicating short periods of absenteeism, for
1–2 days), whereas longer periods of inability to work
(with a medical certificate) did not differ significantly
between the two groups.
clear  and  consistent  associations  were  found  be-
tween HRQol and reduced productivity at work in all
dimensions of the QolRaD. these results confirm
those of another German study. the mean scores in
the group of patients with reduced productivity were
similar to or worse than those of patients with moder-
ate  heartburn  in  the  German  QolRaD  validation
study [15]. there were major differences in HRQol
between patients with and without reduced productivi-
ty in the dimensions “vitality” and “emotional distress”.
this may point to some psychological strain caused by
acute  GERD  symptoms.  “sleep  disturbance”  and
“food/drink problems” were also significantly lower in
patients with reduced productivity, corresponding well
to the finding that nocturnal symptoms are a signifi-
cant predictor of reduced work productivity [24]. 
symptom  severity  (RDQ)  correlates  both  with
HRQol and work productivity. Patients with higher (
i.e., worse)  results on the RDQ had significant more
reduced productivity at work and impaired HRQol.
the RDQ scale “regurgitation” turned out to be the
most  relevant  scale  with  the  largest  difference  and
highest mean score. 
Most  of  the  patients  in  this  study  (61%)  experi-
enced an inability to work or a loss of productivity, al-
though  89%  of  all  patients  were  treated  with  PPIs.
this proportion was higher than the treated patients in
other  studies,  in  which  only  13%–30%  of  patients
took PPI medications [22, 24, 25]. the use of PPI in
this study is similar only to the frequency of PPI-treat-
ed patients (78.4%) in a recent australian investigation
[26]. this high percentage of patients treated with PPI
is  most  likely  due  to  the  inclusion  criteria  (patients
treated with routine clinical care). obviously, the high
rate of patients treated with PPI medication did not
effectively prevent absences from work.
the lack of difference in PPI use between the pa-
tients with and without reduced productivity should
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Table 6. symptom score (Reflux Disease Questionnaire RDQ) in all patients and in patients with normal or reduced productivity.
RDQ scale  Working  no reduced  Reduced Difference P value
patients productivity productivity
total (WPs) (WPs)
n = 249 n = 97 n = 152
Regurgitation 1.67 (1.41) 1.40 (1.39) 1.84 (1.40) –0.44 0.02
Heartburn 1.23 (1.36) 1.00 (1.29) 1.38 (1.39) –0.38 0.04
Dyspepsia 1.48 (1.36) 1.21 (1.35) 1.64 (1.33) –0.43 0.01
GERD (regurgitation+heartburn) 1.45 (1.22) 1.20 (1.20) 1.61 (1.20) –0.41 <0.01
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possible.  In  this  retrospective  study,  patients  with
more-severe symptoms may have been treated with a
higher dose or a more potent PPI than patients who
were  less  affected.  furthermore,  most  patients  may
have been on a demand therapy regimen. the number
of days on which they received PPI medication may
have differed in the two patient groups. However, the
sample  size  in  this  study  was  too  small  to  address
these questions.
the loss of gross domestic product can be estimat-
ed based on the reported days lost to work. the hu-
man capital method uses the full replacement costs, in-
dependent of whether the worker is replaced or not
[27]. based on the human capital method of calculat-
ing the costs of illness, the total loss of gross domestic
product is in the order of 4.2 billion euros annually in
Germany  (1.35  lost  working  days  in  three  months
equals 5.4 lost working days per year, 33 million em-
ployees, 0.14 prevalence of moderate reflux symptoms
[4], ᾬ170/day mean daily gross wage). However, this is
probably an over-estimate. In the present study, only
patients with chronic reflux symptoms who had pre-
sented twice to a physician were included (at least one
visit at least six months before enrolment and a second
visit  3–6  months  before  enrolment).  this  probably
represents a group of patient with severe or refractory
GERD, resulting in a higher number of sick leave days
than in the whole group of GERD patients. there may
also be a selection bias towards patients with increased
numbers  of  sick  leave  days  in  the  preceding  six
months, attributable to the inclusion criteria. However,
if the sick leave days were representative of only one
fifth of the 14% of the population with moderate re-
flux  symptoms,  the  loss  of  gross  domestic  product
would still be in the order of 800 million euros annual-
ly. this estimate is close to the ᾬ668 million/year cal-
culated in the German ProGERD study [10].
stREnGtHs anD lIMItatIons of tHE stuDy
the major strength of our study is that the analysis of
productivity loss was made with the most widely used
GERD-specific validated questionnaire (WPaI–GERD).
to the best of our knowledge, this kind of study has
not been performed before in Germany. thus, the im-
pact of reflux disease on work productivity in a ran-
dom sample of GERD patients was demonstrated and
compared with international results.
the study has several limitations. first, the study is
an observational design, which does not allow for the
direct comparison of different treatment regimens or
for  risk-factor  assessment.  second,  insufficient  data
were available on co-morbidities. therefore we could
not  perform  a  logistic  regression  model  to  analyze
whether  GERD  is  an  independent  predictor  of  the
loss of productivity. However, it can be stated that a
high percentage of German patients with chronic re-
flux disease report a reduced work productivity.
furthermore,  the  respondents  were  recruited  by
primary-care  physicians.  It  can  be  assumed  that  in
Germany, the more-severe cases are treated by office-
based  specialists.  the  consequences  are  unclear  and
range from better treatment with less productivity loss
to a greater impact on work productivity because of
more-severe symptoms.
the  vast  majority  of  patients  were  treated  with
omeprazole. for this reason, no comparison of the ef-
ficacy of various PPIs on work productivity could be
made.  Moreover,  insufficient  data  were  obtained  re-
garding the prescribed therapy regimens (on demand
or daily use of PPIs). the recall period of six months
for the prescribed medication was too short and the
mean number of consultations with the patients was
too low to calculate the average number of tablets tak-
en per day. therefore, these two therapeutic regimens
could not be compared in this study.
conclusIons
GERD has a substantial effect on employees’ produc-
tivity in Germany. obviously, an appreciable produc-
tivity loss exists, even among patients in routine clini-
cal care and undergoing treatment with PPI. symptom
severity and impaired HRQol are significant predic-
tors of reduced work productivity. further investiga-
tions of larger study populations and the inclusion of
patients under specialist care would be beneficial in ex-
amining the reasons for the suboptimal response to
PPI therapy in terms of productivity loss.
Disclosure:  the  study  was  supported  by  an  unrestricted  re-
search grant from astraZeneca GmbH, Wedel, Germany.
REfEREncEs
1. Dent J, El-serag Hb, Wallander Ma, Johansson s. Epi-
demiology of gastro-oesophageal reflux disease: a system-
atic review. Gut 2005 May; 54(5): 710–7.
2. Willich sn, nocon M, kulig M, Jaspersen D, labenz J,
Meyer-sabellek  W,  stolte  M,  lind  t,  Malfertheiner  P.
cost-of-disease  analysis  in  patients  with  gastro-oe-
sophageal  reflux  disease  and  barrett’s  mucosa.  aliment
Pharmacol ther 2006 feb 1;23(3):371-6.
3. kulig M, leodolter a, vieth M, schulte E, Jaspersen D,
labenz  J,  lind  t,  Meyer-sabellek  W,  Malfertheiner  P,
stolte M, Willich sn. Quality of life in relation to symp-
toms in patients with gastro-oesophageal reflux disease—
an  analysis  based  on  the  ProGERD  initiative.  aliment
Pharmacol ther 2003; oct 15;18(8):767-76.
4. nocon M, keil t, Willich sn. Prevalence and sociode-
mographics  of  reflux  symptoms  in  Germany—results
from  a  national  survey.  aliment  Pharmacol  ther  2006
Jun 1;23(11): 1601–5.
5. Hungin  aP,  Raghunath  as,  Wiklund  I.  beyond  heart-
burn: a systematic review of the extra-oesophageal spec-
trum  of  reflux-induced  disease.  fam  Pract.  2005  Dec;
22(6):591-603.
6. Wiklund I. Review of the quality of life and burden of ill-
ness  in  gastroesophageal  reflux  disease.  Dig  Dis  2004;
22(2): 108–14.
7. Ronkainen  J,  aro  P,  storskrubb  t,  lind  t,  bolling-
sternevald E, Junghard o, talley nJ, agreus l. Gastro-
oesophageal  reflux  symptoms  and  health-related  quality
of  life  in  the  adult  general  population  -  the  kalixanda
study. aliment Pharmacol ther 2006 Jun 15;23(12):1725-
33.
8. Wahlqvist P, Reilly Mc, barkun a. systematic review: the
impact of gastro-oesophageal reflux disease on work pro-
ductivity.  aliment  Pharmacol  ther  2006  Jul  15;  24(2):
259-72.
EuRoPEan JouRnal of MEDIcal REsEaRcH March 30, 2010 129
7. Gross_Umbruchvorlage  17.03.10  11:09  Seite 129EuRoPEan JouRnal of MEDIcal REsEaRcH 130 March 30, 2010
9. Wahlqvist P, brook Ra, campbell sM, Wallander Ma,
alexander  aM,  smeeding  JE,  kleinman  nl.  objective
measurement of work absence and on-the-job productivi-
ty: a case–control study of us employees with and with-
out  gastroesophageal  reflux  disease.  J  occup  Environ
Med 2008 Jan;50(1):25-31.
10. leodolter  a,  nocon  M,  kulig  M,  Willich  sn,  Malfer-
theiner P, labenz J. Gastro esophageal reflux disease is
associated  with  absence  from  work:  Results  from  a
prospective  cohort  study.  World  J  Gastroenterol  2005
Dec 7;11(45):7148-51.
11. liker H, Jones R, Ducrotte P. the effect of sleep distur-
bance due to gastroesophageal reflux diesease on work
and leisure productivity: results from a multinational sur-
vey. Gastroenterology 2005; 128: a386
12. Meining a, Driesnack u, classen M, R￶sch t. Manage-
ment of gastroesophageal reflux disease in primary care:
results of a survey in 2 areas in Germany. Z Gastroen-
terol 2002 Jan; 40(1): 15–20.
13. Wiklund Ik, Junghard o, Grace E, talley nJ, kamm M,
veldhuyzen van Zanten s, Par￩ P, chiba n, leddin Ds,
bigard Ma, colin R, schoenfeld P. Quality of life in Re-
flux  and  Dyspepsia  patients.  Psychometric  documenta-
tion of a new disease-specific questionnaire (QolRaD).
Eur J surg suppl 1998; 583: 41–9.
14. crawley J, frank l, Joshua-Gotlib s, flynn J, frank s,
Wiklund I. Measuring change in quality of life in response
to Helicobacter pylori eradication in peptic ulcer disease:
the QolRaD. Dig Dis sci 2001 Mar; 46(3): 571-80.
15. kulich kR, Malfertheiner P, Madisch a, labenz J, bay-
erd￶rffer E, Miehlke s, carlsson J, Wiklund Ik. Psycho-
metric validation of the German translation of the Gas-
trointestinal symptom Rating scale (GsRs) and Quality
of life in Reflux and Dyspepsia (QolRaD) question-
naire  in  patients  with  reflux  disease.  Health  Qual  life
outcomes 2003 oct 28; 1: 62.
16. shaw MJ, talley nJ, beebe tJ, Rockwood t, carlsson R,
adlis s, fendrick aM, Jones R, Dent J, bytzer P. Initial
validation  of  a  diagnostic  questionnaire  for  gastroe-
sophageal reflux disease. am J Gastroenterol 2001 Jan;
96(1): 52-7.
17. nocon M, kulig M, leodolter a, Malfertheiner P, Willich
sn. validation of the Reflux Disease Questionnaire for a
German population. Eur J Gastroenterol Hepatol 2005
feb; 17(2): 229–33.
18. Reilly Mc, Zbrozek as, Dukes EM. the validity and re-
producibility of a work productivity and activity impair-
ment  instrument.  Pharmacoeconomics  1993  nov;  4(5):
353-65.
19. Wahlqvist P, carlsson J, stalhammar no, Wiklund I. va-
lidity  of  a  Work  Productivity  and  activity  Impairment
questionnaire  for  patients  with  symptoms  of  gastro-
esophageal reflux disease (WPaI-GERD)—results from a
cross-sectional  study.  value  Health  2002  Mar-apr;
5(2):106-13.
20. Wahlqvist P. symptoms of gastroesophageal reflux dis-
ease, perceived productivity, and health-related quality of
life. am J Gastroenterol 2001 aug; 96(8 suppl): s57-61.
21. calleja Jl, bixquert M, Maldonado J. Impact of nocturnal
heartburn on quality of life, sleep, and productivity: the
sInERGE study. Dig Dis sci 2007 oct; 52(10): 2858-65.
22. Rey E, Elola-olaso c, Rodr￭guez artalejo f, D￭az-Rubio
M.  Impact  of  gastroesophageal  reflux  symptoms  on
health resource usage and work absenteeism in spain. Rev
Esp Enferm Dig 2006 Jul; 98(7): 518–26.
23. stewart Wf, Ricci Ja, leotta c. Health-related lost pro-
ductive time (lPt): recall interval and bias in lPt esti-
mates. J occup Environ Med 2004 Jun; 46(6 suppl): s12-
22.
24. Dean bb, crawley Ja, schmitt cM, Wong J, ofman JJ.
the burden of illness of gastro-oesophageal reflux dis-
ease:  impact  on  work  productivity.  aliment  Pharmacol
ther 2003 May 15; 17(10): 1309–17.
25. Jones  R,  armstrog  D,  Mnalfertheiner  P,  Ducrott￩  P.
Does  the  treatment  of  gastroesophageal  reflux  disease
(GERD)  meet  patients’  needs?  a  survey-based  study.
curr Med Res opin 2006 april; 22(4): 657–62.
26. kirby cn, Piterman l, nelson MR, Dent J. Gastro-oe-
sophageal  reflux  disease--impact  of  guidelines  on  GP
management. aust fam Physician 2008 Jan-feb; 37(1-2):
73–7.
27. koopmanschap Ma, Rutten ff. a practical guide for cal-
culating  indirect  costs  of  disease.  Pharmacoeconomics
1996 nov;10(5):460-6.
Received: August 20, 2009 / Accepted: September 8, 2009
Address for correspondence:
Prof. Dr. Manfred Gross




7. Gross_Umbruchvorlage  17.03.10  11:09  Seite 130